Revance Therapeutics Investor Presentation — June 2019

Document content

The Next -Generation

Neuromodulator is Here

Investor Presentation | NASDAQ: RVNC

J U N E 20192Forward -Looking Statements / Safe Harbor / Market Data

This presentation contains forward -looking statements, including statements related to: financial metrics, the process and timin g of, and ability to complete, current and anticipated future clinical development of

our investigational product candidates, including anticipated near -term milestones; our business strategy, goals, plans and pros pects; the initiation, enrollment, design, timing and outcome of our clinical trials,

including for the treatment of glabellar (frown) lines, forehead lines, lateral canthal lines (crow’s feet), cervical dystoni a, plantar fasciitis, adult upper limb spasticity and chronic migraine, relating to

DaxibotulinumtoxinA for Injection (DAXI); and related results and reporting of such results and statements; timing of our pot ential BLA submission and regulatory determinations regarding the potential label for

DAXI to treat glabellar (frown) lines and commercial potential of our drug candidates, status of commercial collaborations, i ncluding regulatory approval and related milestones and potential receipt of royalties

under our license agreement with Fosun Pharma and collaboration agreement with Mylan; our ability to obtain, and timing relating to, regulatory approval with respec t to our drug candidates; our ability to

commercialize and launch, and related timelines relating to, our product candidates; the potential aesthetic, therapeutic and economic benefits and value of our product candidates and our technologies; demand

for our product candidates and drivers of demand; market size, adoption rate and potential revenue; growth opportunities and product pipeline; our business strategy, timeline and other goals and market for our

anticipated products, plans and prospects; our ability to leverage our investment in our development and manufacturing platfo rm; our commercial and intellectual property strategy; and our financial and

operating projections, including cash and operating expense forecast.

Forward -looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the

outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development proces s, including the risk that clinical trials may not have an effective design or generate

positive results, or that positive results would assure regulatory approval or commercial success of our product candidates; that we may not obtain the anticipated financial and other benefits of the license